Here, the MOF-gated MS effectively encapsulates the cancer antigen and immunopotentiator, prevents their off-target release, and enhances their targeted delivery to APCs and lymph nodes, resulting in the increase in tumour-specific CD8+ T populations, compared with the MS without MOF. The gene discussed is CD8A; the disease is neoplasm.